SPECIAL NOTICE
A -- Hemorrhage Countermeasure Evaluation Capabilities RFI
- Notice Date
- 4/9/2026 8:07:28 AM
- Notice Type
- Special Notice
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- DEF ADVANCED RESEARCH PROJECTS AGCY ARLINGTON VA 222032114 USA
- ZIP Code
- 222032114
- Solicitation Number
- DARPA-SN-26-61
- Response Due
- 5/4/2026 4:00:00 PM
- Archive Date
- 05/05/2026
- Point of Contact
- Lt. Cmdr. Robert Murray, DARPA/BTO
- E-Mail Address
-
DARPA-SN-26-61@darpa.mil
(DARPA-SN-26-61@darpa.mil)
- Description
- The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) seeks input from industry and academia regarding capabilities for providing independent verification and validation, clinical trial, and commercialization support for hemorrhage countermeasures. This Request for Information (RFI) is a preliminary step to identify potential partners capable of providing third-party assessments of safety and efficacy of potential hemorrhage countermeasures and assisting in development strategies to ensure said products transition from the laboratory to civilian and government markets after research, development, testing, and evaluation (RDT&E) efforts have ended. DARPA is particularly interested in respondents who can address all the above task domains to allow one provider to have comprehensive knowledge about the data for efficiency and to tailor commercialization and regulatory strategies.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/workspace/contract/opp/bfe4d37cb3064e30b2a14f9183c35fbf/view)
- Record
- SN07773748-F 20260411/260409230042 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |